Answer
The dolutegravir component of Triumeq is metabolised primarily by UGT1A1, with a minor CYP3A contribution (9.7% of the total administered dose in a human mass balance study).
Sources for this answer
- Triumeq 50 mg/600 mg/300 mg film-coated tabletsViiV Healthcare UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 33Document updated
Sources checked